Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1797 2
1799 3
1801 2
1803 1
1804 2
1805 1
1807 3
1809 2
1810 1
1813 4
1815 2
1816 2
1817 2
1818 2
1819 2
1820 1
1821 11
1822 2
1823 5
1824 1
1825 5
1826 5
1827 4
1828 8
1829 20
1830 10
1831 6
1832 2
1833 6
1834 5
1835 4
1836 3
1837 1
1838 2
1839 5
1840 5
1841 12
1842 11
1843 10
1844 19
1845 6
1846 12
1847 8
1848 1
1849 3
1850 5
1851 6
1852 6
1853 8
1854 5
1855 10
1856 13
1857 18
1858 32
1859 19
1860 16
1861 11
1862 10
1863 18
1864 19
1865 17
1866 36
1867 18
1868 23
1869 34
1870 23
1871 25
1872 26
1873 26
1874 18
1875 24
1876 15
1877 8
1878 22
1879 35
1880 22
1881 23
1882 36
1883 26
1884 30
1885 30
1886 22
1887 36
1888 33
1889 23
1890 22
1891 20
1892 30
1893 34
1894 46
1895 39
1896 23
1897 19
1898 20
1899 15
1900 17
1901 33
1902 23
1903 20
1904 25
1905 21
1906 28
1907 17
1908 26
1909 36
1910 32
1911 32
1912 48
1913 30
1914 28
1915 29
1916 25
1917 44
1918 34
1919 51
1920 49
1921 48
1922 37
1923 33
1924 31
1925 27
1926 56
1927 49
1928 35
1929 36
1930 43
1931 30
1932 38
1933 36
1934 39
1935 41
1936 49
1937 45
1938 29
1939 63
1940 39
1941 30
1942 30
1943 28
1944 57
1945 304
1946 1205
1947 1159
1948 1361
1949 1330
1950 1620
1951 1942
1952 2171
1953 2197
1954 2113
1955 2276
1956 2272
1957 2325
1958 2181
1959 2081
1960 1943
1961 2661
1962 2447
1963 2871
1964 3843
1965 3508
1966 3826
1967 4400
1968 4972
1969 5491
1970 5061
1971 5350
1972 5584
1973 5444
1974 5435
1975 5823
1976 5583
1977 5837
1978 5873
1979 6105
1980 6055
1981 6355
1982 6794
1983 6903
1984 7044
1985 7692
1986 7447
1987 8101
1988 8249
1989 8892
1990 9064
1991 8907
1992 9251
1993 9298
1994 9378
1995 9698
1996 10087
1997 10323
1998 11024
1999 11164
2000 11538
2001 11675
2002 12307
2003 12901
2004 13578
2005 15053
2006 16635
2007 17114
2008 17893
2009 18275
2010 19179
2011 20516
2012 21663
2013 23742
2014 24931
2015 26425
2016 27815
2017 28802
2018 30179
2019 31265
2020 36388
2021 39686
2022 38226
2023 36484
2024 37115
2025 39445
2026 20587

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

867,560 results

Results by year

Filters applied: . Clear all
Page 1
Ophthalmic nano-bioconjugates: critical challenges and technological advances.
Sanap SN, Bisen AC, Agrawal S, Kedar A, Bhatta RS. Sanap SN, et al. Ther Deliv. 2023 Jul;14(7):419-441. doi: 10.4155/tde-2023-0031. Epub 2023 Aug 3. Ther Deliv. 2023. PMID: 37535389 Review.
Typical ocular anatomy makes topical and systemic ophthalmic drug delivery challenging. Various novel nano-drug delivery approaches are developed to attain the desired bioavailability in the eye by increasing residence time and improved permeability across the corne …
Typical ocular anatomy makes topical and systemic ophthalmic drug delivery challenging. Various novel nano-drug delivery approaches a …
Implementation of anterior segment ophthalmic telemedicine.
Armstrong GW, Liebman DL, Ashourizadeh H. Armstrong GW, et al. Curr Opin Ophthalmol. 2024 Jul 1;35(4):343-350. doi: 10.1097/ICU.0000000000001052. Epub 2024 May 14. Curr Opin Ophthalmol. 2024. PMID: 38813740 Review.
PURPOSE OF REVIEW: The growing push to integrate telemedicine into ophthalmic practices requires physicians to have a thorough understanding of ophthalmic telemedicine's applications, limitations, and recent advances in order to provide well tolerated and appropriat …
PURPOSE OF REVIEW: The growing push to integrate telemedicine into ophthalmic practices requires physicians to have a thorough unders …
The microbiome and ophthalmic disease.
Baim AD, Movahedan A, Farooq AV, Skondra D. Baim AD, et al. Exp Biol Med (Maywood). 2019 Apr;244(6):419-429. doi: 10.1177/1535370218813616. Epub 2018 Nov 21. Exp Biol Med (Maywood). 2019. PMID: 30463439 Free PMC article. Review.
This review describes a growing body of research on relationships between the microbiome and eye disease. Several groups have investigated the microbiota of the ocular surface; dysregulation of this delicate ecosystem has been associated with a variety of pro-inflammatory …
This review describes a growing body of research on relationships between the microbiome and eye disease. Several groups have investi …
Ophthalmic and orbital considerations in the evaluation of skull base malignancies.
Karlin JN, Krauss HR. Karlin JN, et al. J Neurooncol. 2020 Dec;150(3):483-491. doi: 10.1007/s11060-020-03516-6. Epub 2020 May 2. J Neurooncol. 2020. PMID: 32361865 Review.
METHODS: We discuss here the clinical ophthalmologic and orbital considerations in the evaluation of patients with these tumors, as well as the ophthalmic sequelae of treatment with radiation or surgery (or both). And for the surgeon, we discuss the ophthalmic and o …
METHODS: We discuss here the clinical ophthalmologic and orbital considerations in the evaluation of patients with these tumors, as well as …
Updates in ophthalmic pathology.
Mendoza PR, Grossniklaus HE. Mendoza PR, et al. Indian J Ophthalmol. 2017 May;65(5):347-353. doi: 10.4103/ijo.IJO_49_16. Indian J Ophthalmol. 2017. PMID: 28573988 Free PMC article. Review.
Ophthalmic pathology has a long history and rich heritage in the field of ophthalmology. ...Collaborations between ocular oncologists and pathologists allow for improved and comprehensive patient care. Ophthalmic pathology continues to be a relevant specialty that i …
Ophthalmic pathology has a long history and rich heritage in the field of ophthalmology. ...Collaborations between ocular oncologists …
Research progress of ophthalmic preparations of immunosuppressants.
Liu Y, Xu H, Yan N, Tang Z, Wang Q. Liu Y, et al. Drug Deliv. 2023 Dec;30(1):2175925. doi: 10.1080/10717544.2023.2175925. Drug Deliv. 2023. PMID: 36762580 Free PMC article. Review.
Immune ophthalmopathy is a collection of autoimmune eye diseases. Immunosuppressants are drugs that can inhibit the body's immune response. Considering drug side effects such as hepatorenal toxicity and the unique structure of the eye, incorporating immunosuppressan …
Immune ophthalmopathy is a collection of autoimmune eye diseases. Immunosuppressants are drugs that can inhibit the body's immune res …
Anterior Segment Imaging Devices in Ophthalmic Telemedicine.
Armstrong GW, Kalra G, De Arrigunaga S, Friedman DS, Lorch AC. Armstrong GW, et al. Semin Ophthalmol. 2021 May 19;36(4):149-156. doi: 10.1080/08820538.2021.1887899. Epub 2021 Mar 3. Semin Ophthalmol. 2021. PMID: 33656960 Review.
The ability of these devices to identify various ophthalmic diseases has been studied, including cataracts, as well as abnormalities of the ocular adnexa, cornea, and anterior chamber. This article reviews the current state of anterior segment imaging for the purpose of …
The ability of these devices to identify various ophthalmic diseases has been studied, including cataracts, as well as abnormalities …
Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
Sall K, Stevenson OD, Mundorf TK, Reis BL. Sall K, et al. Ophthalmology. 2000 Apr;107(4):631-9. doi: 10.1016/s0161-6420(99)00176-1. Ophthalmology. 2000. PMID: 10768324 Clinical Trial.
OBJECTIVE: To compare the efficacy and safety of cyclosporin A ([CsA] 0.05% and 0.1% ophthalmic emulsions) to vehicle in patients with moderate to severe dry eye disease. DESIGN: Multicenter, randomized, double-masked, parallel-group, 6-month, vehicle-controlled. .. …
OBJECTIVE: To compare the efficacy and safety of cyclosporin A ([CsA] 0.05% and 0.1% ophthalmic emulsions) to vehicle in patients wit …
Ophthalmic drug delivery systems--recent advances.
Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. Bourlais CL, et al. Prog Retin Eye Res. 1998 Jan;17(1):33-58. doi: 10.1016/s1350-9462(97)00002-5. Prog Retin Eye Res. 1998. PMID: 9537794 Review.
Eye-drops are the conventional dosage forms that account for 90% of currently accessible ophthalmic formulations. ...To improve ocular drug bioavailability, there is a significant effort directed towards new drug delivery systems for ophthalmic administration …
Eye-drops are the conventional dosage forms that account for 90% of currently accessible ophthalmic formulations. ...To improv …
Polymer-based carriers for ophthalmic drug delivery.
Imperiale JC, Acosta GB, Sosnik A. Imperiale JC, et al. J Control Release. 2018 Sep 10;285:106-141. doi: 10.1016/j.jconrel.2018.06.031. Epub 2018 Jun 30. J Control Release. 2018. PMID: 29964135 Review.
Despite the wide range of diseases affecting the eye, ocular bioavailability remains a challenge in ophthalmic drug delivery. Nowadays an extensive variety of polymers are being explored to develop colloidal drug carriers which show better performance than the more …
Despite the wide range of diseases affecting the eye, ocular bioavailability remains a challenge in ophthalmic drug delivery. …
867,560 results
You have reached the last available page of results. Please see the User Guide for more information.